Does Lurbinectedin Cause Allergic Reactions?
Yes, lurbinectedin (brand name Zepzelca) can cause allergic reactions, though they are not among the most common side effects. The prescribing information lists hypersensitivity reactions as a potential risk, which may include symptoms like rash, itching, flushing, shortness of breath, or anaphylaxis in severe cases.[1]
What Allergic Symptoms Have Been Reported?
Reported hypersensitivity reactions range from mild skin reactions (e.g., urticaria or hives) to severe events requiring intervention. In clinical trials, these occurred in about 1-5% of patients, often during or shortly after infusion. Symptoms can appear within hours and may worsen with repeated doses.[1][2]
How Is Allergic Risk Managed During Treatment?
Premedication is standard to reduce hypersensitivity risk: patients typically receive dexamethasone, an H1 antagonist (like diphenhydramine), and an H2 antagonist (like ranitidine or famotidine) before each infusion. Infusions start slowly (over 60 minutes) and are monitored closely. Treatment stops if severe reactions occur, with epinephrine or other emergency measures available.[1]
Who Is Most at Risk for Reactions?
Patients with a history of allergies to platinum drugs (like cisplatin) or prior hypersensitivity to chemotherapy may face higher risk, as lurbinectedin is often combined with these. No specific genetic markers are identified, but monitoring is critical in the first cycles.[1][2]
What If an Allergic Reaction Happens?
Mild reactions may resolve with supportive care, but severe ones (Grade 3-4) lead to permanent discontinuation in most cases. Post-reaction desensitization protocols exist for some chemotherapies but are not standard for lurbinectedin. Consult oncology guidelines or report to FDA MedWatch.[1][3]
[1]: Zepzelca Prescribing Information (FDA)
[2]: Clinical Pharmacology Review (FDA)
[3]: NCCN Guidelines for Small Cell Lung Cancer (2023)